Linomide, a synthetic quinoline carboxamide, has the ability to stimulate various lymphocyte subpopulations. We have shown its inhibitory effect on the clinical and histological signs of acute and chronic relapsing EAE. In these models linomide induces suppression of lymphocyte response to antigens, production of autoantibody, antigen presentation to specific T-cell lines and Mac-1 expression, and induces activation of NK and suppressor-inducer cells. We have subsequently shown its inhibitory effect on clinical and MRI signs of patients with secondary progressive multiple sclerosis. Results of a double blind, placebo controlled, short term pilot study with p.o. linomide, showed a significant effect on the clinical disability scale (EDSS) (P=0.045) and on the mean total number of new lesions in serial monthly MRI scans (P=0.021). The increase of CD45Ra, CD8 and CD16 positive cells in linomide treated patients may indicate the importance of suppressor-inducer, suppressor and NK cells for the inhibition of the autoimmune response in the disease.
1 Ransohoff RM. (1992) Pathogenesis of multiple sclerosis: Relationship to therapeutic strategies. In: Rudick RA & Goodkin DE (eds). Treatment of multiple sclerosis: trial design, results, and future perspectives.Springer-Verlag: London, pp 123–133.
2.
2 Hafler DA, Weiner HL. (1989) Multiple sclerosis: a CNS and systemic autoimmune disease. Immunol Today10: 104–107.
3.
3 Weiner HL, Hafler DA. (1988) Immunotherapy of multiple sclerosis. Ann Neurol23: 211–222.
4.
4 Bansil S, Cook SD, Rohowsky-Kochon C. (1995) Multiple sclerosis: Immune mechanism and update on current therapies. Ann Neurol37: 87–101.
5.
5 Merrill J et al. (1982) Decreased NK killing in patients with MS: an analysis on the level of the single effector cell in peripheral blood and cerebrospinal fluid in relation to the activity of the disease. Clin Exp Immunol47: 419–430.
6.
6 Neighbour PA, Miller AC, Bloom BR. (1981) Interferon responses of leucocytes in multiple sclerosis. Neurology31: 561–566.
7.
7 Noronha A, Toscas A, Jensen MA. (1990) Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol27: 207–210.
8.
8 Sharief MK, Hentges R. (1991) Association between tumor necrosis factor-a and disease progression in patients with multiple sclerosis. N Engl J Med325: 467–472.
9.
9 Bengtsson M, Simonsson B, Carlsson K et al. (1992) Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator linomide after autologous bone marrow transplantation. A pilot study in patients wtih acute myeloid leukemia.Transplantation53, 882–888.
10.
10 Kalland T. (1990) Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J Immunol144: 4472–4476.
11.
11 Kalland T, Aim G, Stalhandske T. (1985) Augmentation of mouse natural killer activity by LS-2616, a new immunomodulator. J Immunol134: 3956–3961.
12.
12 Stalhandske T, Eriksson E, Sandberg BM. (1982) A novel quinoline-carboxamide with interesting immunomodulating activity. Int J Immunopharmacol4: 336.
13.
13 Harning R, Szalay J. (1988) A treatment for metastasis of murine ocular melanoma. InvestOphthalm & Visual Science29: 1505–1510.
14.
14 Kalland T. (1986) Effects of immunomodulator LS2616 on growth and metastasis of the murine B16–F10 melanoma. Cancer Res46: 3018–3022.
15.
15 Larsson EL, Joki A, Stalhandske T. (1987) Mechanism of action of the new immunomodulator LS-2616 on T-cell responses. Int J Immunopharmacol9: 425–431.
16.
16 Karussis DM et al. (1993) Inhibition of acute-EAE with linomide (LS-2616), an activator of natural killer cells. Ann Neurol34: 654.
17.
17 Karussis DM et al. (1993) Treatment of chronic-relapsing experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA90: 6400–6404.
18.
18 Lehmann D et al. (1996) Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through downregulation of macrophage activity in the model of experimental autoimmune encephalomyelitis (EAE) (submitted).
19.
19 Karussis D et al. (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a pilot double-blind placebo controlled study with monthly MRI evaluation.Neurology (in press).
20.
20 Nauta JJP, Thompson AJ, Barkhoff, Miller DH. (1994) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: statistical analysis power of parallel-groups and crossover designs. J Neurol Sci122: 6–14.
21.
21 Frank JA et al. (1994) Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol36: S86–S90.
22.
22 Poser CM, Paty DW, Scheinberg L et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. AnnNeurol13: 227–231.
23.
23 Kurtzke FJ. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology33: 1444–1452.
24.
24 Anderson O et al. (1996) Linomide reduces the rate of active lesions in relapsing remitting multiple sclerosis.Neurology (in press).
25.
25 Morimoty C, Letvin NL, Aldrich WR, Schlossman SF. (1985) The isolation and characterization of the human suppressor inducer T cell subset. J Immunol134: 1508–1515.
26.
26 Morimoto C, Hafler DA, Weiner HL et al. (1987) Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. N Engl J Med316: 67–72.
27.
27 Khoury SJ, Guttmann C, Ahn S et al. (1993) Correlation between MRI and immunologic studies in MS patients. Neurology43: 182.
